Navigation Links
Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
Date:11/6/2012

CRANBURY, N.J. and CAMBRIDGE, Mass., Nov. 6, 2012 /PRNewswire/ -- Oncobiologics, Inc. and Boston Oncology, LLC today announced a strategic partnership that will allow Boston Oncology to license, manufacture, and commercialize four of Oncobiologics' biosimilar therapies for cancer and immunological disease in the Middle East and North African (MENA) regions.

Under the agreement, Boston Oncology—a pharmaceutical company that localizes advanced technologies and manufacturing expertise in the developing world—will provide Oncobiologics with upfront licensing payments and development milestone payments, along with royalties after the medicines are commercialized. Boston Oncology plans to oversee clinical trials and the development of manufacturing facilities for these therapies in various MENA markets.

The four biosimilars under agreement are generic versions of the most popular therapies in the world for their indications, representing annual global revenue of more than $25 billion.

"This partnership represents a critical step in Boston Oncology's mission to provide people in emerging nations with cost-effective, locally-produced therapeutics for cancers and inflammatory diseases," said Boston Oncology Founder and CEO Abdullah Baaj, M.D., Pharm. D. "Oncobiologics has a rigorous R&D program that will allow us to bring biosimilar therapies to the Middle East and North Africa."

"We are thrilled to announce this strategic alliance with Boston Oncology, which represents the perfect partner for launching Oncobiologics' first four biosimilar molecules in the MENA region," said Pankaj Mohan, Ph.D., CEO of Oncobiologics. "Boston Oncology has built an innovative, forward-looking model that will bring affordable, therapeutically important medicines to emerging markets," he said.

Specific financial terms were not disclosed. 

About Oncobiologics, Inc.
Oncobiologics is a biopharmaceutical company developing a pipeline of biosimilars and next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Formed by a team of leading industry experts, Oncobiologics operates from a state-of-the-art R&D facility in Cranbury, NJ. Together with its biosimilars licensing partner, Parilis Biopharmaceuticals, Oncobiologics is actively pursuing commercial partner­ship opportunities. For more information, please visit www.oncobiologics.com or call 609-619-3990.

About Boston Oncology, LLC
Boston Oncology, LLC is a privately held company headquartered in Cambridge, Massachusetts, USA. Registered in 2012, Boston Oncology acquires, manages, and transfers intellectual property to locally produce generic chemotherapy and biologic pharmaceuticals in developing nations and emerging markets across the world. Visit www.bostononcology.com. Contact:ONCOBIOLOGICS, INC.BUSINESS & TECHNICAL INQUIRIESStephen J. McAndrew, Ph.D.609-619-3990, ext. 216stephenmcandrew@oncobiologics.com MEDIA INQUIRIESRick Gregory860-677-2377rickgregory@oncobiologics.comBOSTON ONCOLOGY, LLCBUSINESS INQUIRIESZeshawn Beg, DBA, CMACFO, Boston Oncology, LLC617-800-9439zbeg@bostononcology.com MEDIA INQUIRIESSarah Welch DeMayoVibrancy Communications781-727-7516sarah@vibrancycom.com This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael F. Mahoney Assumes Role of Chief Executive Officer and President of Boston Scientific
2. Varian Medical Systems to Proceed with Year End Review and Webcast for Investors at ASTRO Meeting in Boston
3. Boston Scientific to Acquire BridgePoint Medical, Inc.
4. MD+DI Announces Wireless Connectivity in Medical Devices EAST Conference in Boston, MA
5. Boston Scientific to Participate in the 2012 Morgan Stanley Global Healthcare Conference
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
7. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
8. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
9. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
10. Boston Scientific to Announce Second-Quarter 2012 Financial Results on July 26
11. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  The U.S. Food ... (avelumab) for the treatment of adults and pediatric patients ... (MCC), including those who have not received prior chemotherapy. ... a rare, aggressive form of skin cancer. ... cancers, patients with a rare form called Merkel cell ...
(Date:3/23/2017)... DIEGO and VANCOUVER, British Columbia ... (NASDAQ: SPHS ) (the "Company" or "Sophiris"), ... the treatment of urological diseases, today announced that data ... evaluated the drug as a focal treatment for localized ... March 26, 2017 at the 32 nd Annual ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... Devices Market 2017-2021" report to their offering. ... The global oxygen therapy devices ... 2017-2021. The report, Global Oxygen Therapy Devices Market ... inputs from industry experts. The report covers the market landscape and ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced ... The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive ... that have excellent programs for the delivery and improvement of disease management and ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... educational training program owned and organized by HMP Communications Holdings, LLC, today announced ... for physicians within its nationwide network of wound centers interested in becoming Certified ...
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... ... serving the families and businesses of the greater Fort Collins area, has unveiled ... in their ongoing community involvement program. Donations to this worthy cause may now ...
(Date:3/23/2017)... ... , ... After raising more than $1.135 million ($1,479,231 AUD) from nearly 20,000 ... in crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle USA, ... “We’re excited to be operating on U.S. shores, where most of our initial crowdfunding ...
Breaking Medicine News(10 mins):